Dell Technologies Inc vs DexCom, Inc. — how do they compare? Dell Technologies Inc trades at $468.46 (market cap $284.93B), while DexCom, Inc. trades at $90.14 (market cap $33.79B). The key difference: Dell Technologies Inc is far larger — about 8.4× DexCom, Inc.'s market cap, and Dell Technologies Inc pays a 0.57% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DELL | DXCM | |
|---|---|---|
Market Cap | $284.93B | $33.79B |
Sector | Technology | Health |
52-Week High | $467.27 | $89.53 |
52-Week Low | $111.10 | $54.84 |
Enterprise Value | $304.51B | $33.24B |
Dividend Yield | 0.57% | — |
Signals from Pluang's Aura AI — not financial advice
Dell Technologies stock trades at $467.28, up 2.04% today, with strong bullish momentum driven by AI server demand and consistent earnings beats. The technical outlook is bullish with moving averages supporting upward trends, while fundamentals show revenue growth to $95.57B in 2025 and a net income margin of 6.28%. Analyst consensus is positive with a $503.76 price target, reflecting optimism around Dell's positioning in the AI infrastructure market.
The outlook for Dell remains favorable due to robust AI-driven server demand and solid financial performance, though risks include valuation concerns at a P/E of 35.14 and competitive pressures. Investors should weigh the growth potential against potential margin compression and market volatility.
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
Trailing returns across standard periods
Latest headlines on both assets
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →